Final overall survival results from a Phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)

Journal of Thoracic Oncology

Volumn 10, Issue 4, 2015, Pages 655-664

  Zhao, Hongyun ^a,b   Fan, Yun ^c   Ma, Shenglin ^d   Song, Xiangqun ^e   Han, Baohui ^f   Cheng, Ying ^g   Huang, Cheng ^h   Yang, Shujun ⁱ   Liu, Xiaoqing ^j   Liu, Yunpeng ^k   Lu, Shun ^l   Wang, Jie ^m   Zhang, Shucai ⁿ   Zhou, Caicun ^o   Wang, Mengzhao ^p   Zhang, Li ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^e Department of Interventional Therapy   (China)

^f SHANGHAI CHEST HOSPITAL   (China)

^g Jilin Province Tumour Hospital   (China)

^h FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

ⁱ The Agriculture Department of Henan Province   (China)

^j Beijing 307 Hospital   (China)

^k CHINA MEDICAL UNIVERSITY   (China)

^l SHANGHAI JIAO TONG UNIVERSITY   (China)

^m PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

ⁿ CAPITAL MEDICAL UNIVERSITY   (China)

^o TONGJI UNIVERSITY   (China)

^p PEKING UNION MEDICAL COLLEGE   (China)

more..

Author keywords

Gefitinib; INFORM; Maintenance; NSCLC; OS

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLACEBO; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC NON SMALL CELL LUNG CANCER; MULTICENTER STUDY; MUTATION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WILD TYPE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CLINICAL TRIAL; EPIDEMIOLOGY; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TRENDS; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930934298     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000445     Document Type: Article

References (33)

1. Schiller JH, Harrington D, Belani CP, Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 346 92 98
2. Ohe Y, Ohashi Y, Kubota K, Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007 18 317 323
3. Ciuleanu T, Brodowicz T, Zielinski C, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009 374 1432 1440
4. Brodowicz T, Krzakowski M, Zwitter M, Central European Cooperative Oncology Group CECOG Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006 52 155 163
5. Pérol M, Chouaid C, Pérol D, Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012 30 3516 3524
6. Gridelli C, Maione P, Rossi A, Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 2009 14 137 147
7. Azzoli CG, Temin S, Aliff T, American Society of Clinical Oncology 2011 Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011 29 3825 3831
8. Fidias P, Novello S, Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010 28 5116 5123
9. Behera M, Owonikoko TK, Chen Z, Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-Analysis. Lung Cancer 2012 77 331 338
10. Coudert B, Ciuleanu T, Park K, SATURN Investigators Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012 23 388 394
11. Sato M, Shames DS, Gazdar AF, Minna JD, A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007 2 327 343
12. Tang X, Shigematsu H, Bekele BN, EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005 65 7568 7572
13. Takeda K, Hida T, Sato T, Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010 28 753 760
14. Gaafar RM, Surmont VF, Scagliotti GV, EORTC Lung Cancer Group and the Italian Lung Cancer Project A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 2011 47 2331 2340
15. Xu JM, Han Y, Li YM, Zhao CH, Wang Y, Paradiso A, Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer. BMC Cancer 2006 6 288
16. Rosell R, Moran T, Queralt C, Spanish Lung Cancer Group Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009 361 958 967
17. Zhu CQ, da Cunha Santos G, Ding K, National Cancer Institute of Canada Clinical Trials Group Study BR.21 Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008 26 4268 4275
18. Mitsudomi T, Morita S, Yatabe Y, West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010 11 121 128
19. Maemondo M, Inoue A, Kobayashi K, North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 362 2380 2388
20. Mitsudomi T, Kosaka T, Endoh H, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005 23 2513 2520
21. Han SW, Kim TY, Hwang PG, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005 23 2493 2501
22. Zhang L, Ma S, Song X, INFORM Investigators Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012 13 466 475
23. Pocock SJ, Simon R, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975 31 103 115
24. Fukuoka M, Wu YL, Thongprasert S, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011 29 2866 2874
25. Jackman DM, Miller VA, Cioffredi LA, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009 15 5267 5273
26. Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 361 947 957
27. Han JY, Park K, Kim SW, First-SIGNAL: first-line single-Agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012 30 1122 1128
28. Cappuzzo F, Ciuleanu T, Stelmakh L, SATURN Investigators Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010 11 521 529
29. Rosell R, Wannesson L, A genetic snapshot of small cell lung cancer. Cancer Discov 2012 2 769 771
30. Zhang JW, Zhao YY, Guo Y, The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer. Chin J Cancer 2014 33 105 114
31. Zhou C, Wu YL, Liu X, Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2012 30 7520
32. Shigematsu H, Lin L, Takahashi T, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005 97 339 346
33. Wu YL, Zhong WZ, Li LY, Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-Analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007 2 430 439